Compare Inovio Pharmaceuticals Inc (INO) vs Open Text Corporation (OTEX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Open Text Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $112.19M), while Open Text Corporation trades at $23.56 (market cap $5.61B). The key difference: Open Text Corporation is far larger — about 50× Inovio Pharmaceuticals Inc's market cap, and Open Text Corporation pays a 4.82% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Open Text Corporation for 23 Days on average.
| INO | OTEX | |
|---|---|---|
Market Cap | $112.19M | $5.61B |
Volume | 3,201,278 | 1,197,475 |
Sector | Health | Technology |
52-Week High | $2.65 | $39.69 |
52-Week Low | $0.66 | $20.01 |
Typical Hold Time | 43 Days | 23 Days |
Enterprise Value | $83.51M | $10.63B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
OTEX trades at $23.52, up 1.64% today, with a bearish technical signal despite recent earnings beats. The stock is attractively valued with a P/E of 9.01 and P/S of 1.1, supported by strong profitability margins. Recent news highlights debt restructuring and a strategic AI partnership with Cohere, while cash flow trends show operational strength but negative net cash flow.
The outlook is mixed: valuation discounts and cloud growth present opportunity, but high debt and bearish technicals pose risks. Analyst consensus is a Buy with a $28.30 target, implying potential upside, though execution on AI initiatives and debt management will be critical for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Open Text Corporation
Open Text Corporation is a global leader in Enterprise Information Management (EIM) software and solutions. The company provides a comprehensive platform that helps organizations manage, secure, and leverage their unstructured digital content, including documents, emails, and media files. OTEX's offerings span content management, business process management, customer experience management, and security, serving large enterprises across various industries worldwide.
Read more on OTEX →
